Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies

Journal of Gastrointestinal Surgery

Volumn 17, Issue 12, 2013, Pages 2123-2132

  Dodson, Rebecca M ^a   Firoozmand, Amin ^a   Hyder, Omar ^a   Tacher, Vania ^a   Cosgrove, David P ^a   Bhagat, Nikhil ^a   Herman, Joseph M ^a   Wolfgang, Christopher L ^a   Geschwind, Jean Francois H ^a   Kamel, Ihab R ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Frailty; Intra arterial therapy; Outcomes; Performance status; Sarcopenia

Indexed keywords

AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; BODY MASS; CHEMOEMBOLIZATION; COLORECTAL TUMOR; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAHEPATIC BILE DUCT; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PSOAS MUSCLE; SARCOPENIA;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSOAS MUSCLES; SARCOPENIA;

EID: 84888273092     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2348-5     Document Type: Article

References (56)

1. Breedis C, Young G. The blood supply of neoplasms in the liver. The American journal of pathology. 1954;30(5): 969-77.
2. Goldberg JA, Kerr DJ, Stewart I, McArdle CS. A comparison of regional and systemic chemotherapy for hepatic metastases. European journal of surgical oncology. 1990;16(5): 464-7.
3. Cohen AM, Kemeny NE, Kohne CH, Wils J, de Takats PG, Kerr DJ. Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Eur J Cancer. 1996;32A(13): 2195-205.
4. Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. American journal of surgery. 2007;194(1): 79-88.
5. Memon K, Lewandowski RJ, Riaz A, Salem R. Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Current treatment options in oncology. 2012;13(3): 403-15.
6. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3): 641-57.
7. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319): 1734-9.
8. Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(2): 526-35, 35 e1-2.
9. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117(2): 343-52.
10. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009;250(1): 281-9.
11. Brown RE, Gibler KM, Metzger T, Trofimov I, Krebs H, Romero FD, et al. Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: early outcomes from a multi-institutional registry. The American surgeon. 2011;77(1): 93-8.
12. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1): S194-205.
13. Hendlisz A, van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Journal of clinical oncology. 2010;28(23): 3687-94.
14. Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Alimentary pharmacology & therapeutics. 2011;34(2): 196-204.
15. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB. 2010;12(3): 174-80.
16. Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR American journal of roentgenology. 2011;196(4): 919-28.
17. Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver transplantation. 2011;17(5): 556-66.
18. Tsai YJ, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatology international. 2011; 5(4): 975-984.
19. Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ, Chen MS. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Chinese journal of cancer. 2010;29(2): 172-7.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5): 1208-36.
21. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A(7): 1135-41.
22. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology. 1996;48(3): 373-8.
23. Maltoni M, Nanni O, Derni S, Innocenti MP, Fabbri L, Riva N, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer. 1994;30A(6): 764-6.
24. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Archives of internal medicine. 1988;148(7): 1586-91.
25. Khan RB, Sanford RA, Kun LE, Thompson SJ. Morbidity of second-look surgery in pediatric central nervous system tumors. Pediatric neurosurgery. 2001;35(5): 225-9.
26. Cheng AL, Yeh KH, Fine RL, Chuang SE, Yang CH, Wang LH, et al. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepato-gastroenterology. 1998;45(24): 1955-60.
27. Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. Journal of clinical oncology. 2001;19(15): 3539-46.
28. Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M, Li H, et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer. 2008;113(8): 2205-14.
29. Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, et al. Frailty as a predictor of surgical outcomes in older patients. Journal of the American College of Surgeons. 2010;210(6): 901-8.
30. Cawthon PM, Fox KM, Gandra SR, Delmonico MJ, Chiou CF, Anthony MS, et al. Do muscle mass, muscle density, strength, and physical function similarly influence risk of hospitalization in older adults? Journal of the American Geriatrics Society. 2009;57(8): 1411-9.
31. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. Journal of clinical oncology. 2010;28(6): 1054-60.
32. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. Journal of the American College of Surgeons. 2010;211(2): 271-8.
33. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. Journal of gastrointestinal surgery. 2012;16(8): 1478-86.
34. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical cancer research. 2009;15(8): 2920-6.
35. Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Annals of surgical oncology. 2011;18(13): 3579-85.
36. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB. 2011;13(7): 439-46.
37. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. Journal of clinical oncology. 2010;28(2): 340-7.
38. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Annals of oncology. 2010;21(8): 1594-8.
39. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Annals of surgery. 2009;250(2): 187-96.
40. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. American journal of epidemiology. 1998;147(8): 755-63.
41. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97(6): 2333-8.
42. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5): 997-1006.
43. Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19(5): 1115-23.
44. Allgaier HP, Deibert P, Olschewski M, Spamer C, Blum U, Gerok W, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. International journal of cancer Journal international du cancer. 1998;79(6): 601-5.
45. Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer. 2000;88(1): 50-7.
46. El Khaddari S, Gaudin JL, Abidi H, Picaud G, Rode A, Souquet JC. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session]. Gastroenterologie clinique et biologique. 2002;26(8-9): 728-34. Chimio-embolisation des carcinomes hepatocellulaires: analyse multivariee des facteurs pronostiques de survie apres la premiere seance.
47. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. Journal of vascular and interventional radiology: JVIR. 2005;16(2 Pt 1): 195-203.
48. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008;247(2): 507-15.
49. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. The British journal of surgery. 2012;99(4): 550-7.
50. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62: 265-79.
51. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006;83(6): 1345-50.
52. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(10): 1059-64.
53. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11): 1993-7.
54. Park SW, Goodpaster BH, Strotmeyer ES, Kuller LH, Broudeau R, Kammerer C, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30(6): 1507-12.
55. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR, Harris TB. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis international. 2010;21(4): 543-59.
56. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clinical cancer research. 2009;15(22): 6973-9.